Logo Image

Eleonora Teplinsky, MD

Articles by Eleonora Teplinsky, MD

Treatment on Molecular Recurrence and Access Barriers

ByJohn Strickler, MD,Petros Grivas MD, PhD,Luis E. Raez, MD,Eleonora Teplinsky, MD,Benjamin Weinberg, MD

Dr. Weinberg explains the treatment on molecular recurrence (TOMR) concept, drawing parallels to biochemical relapse monitoring in prostate cancer. In colorectal cancer, patients with positive ctDNA after completing curative-intent surgery and adjuvant chemotherapy will experience radiographic recurrence at a median of approximately 5.5 months, representing a population potentially amenable to curative intervention through escalated imaging to identify oligometastatic disease suitable for metastasectomy, or enrollment in novel drug development trials.

Clinical Workflow Integration for ctDNA Testing and Patient Communication

ByJohn Strickler, MD,Petros Grivas MD, PhD,Luis E. Raez, MD,Eleonora Teplinsky, MD,Benjamin Weinberg, MD

Dr. Teplinsky addresses where ctDNA and MRD testing fit within the patient care continuum, noting that value isn't uniform across disease stages or tumor types. The strongest signal currently exists in the post-treatment surveillance setting, where tumor-informed assays can identify patients at higher recurrence risk before disease becomes visible on imaging.

Foundations of ctDNA and MRD Testing

ByJohn Strickler, MD,Petros Grivas MD, PhD,Luis E. Raez, MD,Eleonora Teplinsky, MD,Benjamin Weinberg, MD

Dr. John Strickler introduces the program on circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing across solid tumors, joined by Dr. Eleonora Teplinsky (breast and gynecologic oncology, Valley Health System), Dr. Ben Weinberg (gastrointestinal oncology, Georgetown University), Dr. Petros Grivas (genitourinary oncology, Fred Hutchinson Cancer Center), and Dr. Luis Raez (thoracic oncology, Memorial Healthcare System).

Latest Updated Articles